Abstract
Importance Retinal ganglion cells endure significant metabolic stress in glaucoma but maintain capacity to recover function. Nicotinamide, a precursor of NAD+, is low in serum of glaucoma patients and its supplementation provides robust protection of retinal ganglion cells in preclinical models. However, the potential of nicotinamide in human glaucoma is unknown.
Background To determine whether nicotinamide supplementation alongside conventional IOP-lowering therapy improves retinal ganglion cell function in glaucoma.
Design Crossover, double-masked, randomised clinical trial. Participants recruited from two tertiary care centres.
Participants Fifty-seven participants, diagnosed and treated for primary glaucoma, enrolled.
Methods Participants received oral placebo or nicotinamide and reviewed six-weekly. Participants commenced 6-weeks of 1.5 grams/day then 6 weeks of 3.0 grams/day followed by crossover without washout. Visual function measured using electroretinography and perimetry.
Main outcome measures Change in inner retinal function, determined by photopic negative response (PhNR) parameters: saturated PhNR amplitude (Vmax), ratio of PhNR/b-wave amplitude (Vmax ratio).
Results PhNR Vmax improved beyond 95% coefficient of repeatability (COR) in 23% of participants following nicotinamide versus 9% on placebo. Overall, Vmax improved by 14.8% [95% CI: 2.8%, 26.9%], (p=0.02) on nicotinamide and 5.2% [−4.2%, 14.6%], (p=0.27) on placebo. Vmax ratio improved by 12.6% [5.0%, 20.2%], (p=0.002) following nicotinamide, 3.6% [−3.4%, 10.5%], (p=0.30) on placebo. A trend for improved visual field mean deviation was observed with 27% improving ≥1dB on nicotinamide and fewer deteriorating (4%) compared to placebo (p=0.02).
Conclusions Nicotinamide supplementation can improve inner retinal function in glaucoma. Further studies underway to elucidate the effects of long-term nicotinamide supplementation.
Trial Registration ANZCTR trial ID: ACTRN12617000809336 https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373001
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ACTRN12617000809336
Clinical Protocols
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373001
Funding Statement
Ophthalmic Research Institute of Australia (FH); Jack Brockhoff Foundation, Marian and E.H. Flack Trust – JBF Grant number 4354 – 2017 (FH); Jean Miller Foundation (JGC); Connie and Craig Kimberley Fund (IAT, JGC). Board of Research Faculty Funded Career position (Karolinska Institutet) (PAW). The Centre for Eye Research Australia receives operational infrastructure support from the Victorian Government. The funding organisations had no role in the design or conduct of this research.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial support: Ophthalmic Research Institute of Australia (FH); Jack Brockhoff Foundation, Marian and E.H. Flack Trust – JBF Grant number 4354 – 2017 (FH); Jean Miller Foundation (JGC); Connie and Craig Kimberley Fund (IAT, JGC). Board of Research Faculty Funded Career position (Karolinska Institutet) (PAW). The Centre for Eye Research Australia receives operational infrastructure support from the Victorian Government. The funding organisations had no role in the design or conduct of this research.
Abbreviations and Acronyms: ATP - adenosine triphosphate, CI – confidence interval, COR – coefficient of repeatability, ERG – electroretinogram, IOL – intraocular lens, IOP – intraocular pressure, IQR – interquartile range, MD – mean deviation, MLS – mean light sensitivity, NAD+ – nicotinamide adenine dinucleotide, NAM – nicotinamide, PL – placebo, POAG – primary open-angle glaucoma, PhNR – photopic negative response, PSD – pattern standard deviation, Q1 – lower quartile, Q3 – upper quartile, RGC – retinal ganglion cell, RNFL – retinal nerve fibre layer, VF – visual field, Vmax – saturating amplitude
Conflict of interest: No conflicting relationship exists for any author.
Data sharing statement: Clinical data was collected at the Centre for Eye Research Australia in collaboration with the Royal Victorian Eye and Ear Hospital and Melbourne Eye Specialists. These data are not publicly available. Source data of graphs may be available as source files if requested. A description of the code used to analyse the electroretinogram data is described in the Methods section, and we have also published this previously (Tang et al, 2018).
Data Availability
Clinical data was collected at the Centre for Eye Research Australia in collaboration with the Royal Victorian Eye and Ear Hospital and Melbourne Eye Specialists. These data are not publicly available. Source data of graphs may be available as source files if requested. A description of the code used to analyze the electroretinogram data is described in the Methods section, and we have also published this previously (Tang et al, 2018).
